Insider Trading Activity Flexion Therapeutics Inc. (NASDAQ:FLXN) – Insider Sold 10,000 shares of Stock

ME Staff
-
0

Insider Trading Activity For Flexion Therapeutics Inc. (NASDAQ:FLXN)

Neil Bodick , Insider of Flexion Therapeutics Inc. (NASDAQ:FLXN) reportedly Sold 10,000 shares of the company’s stock at an average price of 18.46 for a total transaction amount of $184,600.00 SEC Form

Insider Trading History For Flexion Therapeutics Inc. (NASDAQ:FLXN)

  • On 2/18/2014 Sofinnova Partners Sas, Major Shareholder, bought 230,769 with an average share price of $13.00 per share and the total transaction amounting to $2,999,997.00.
  • On 2/18/2014 Bradley J Phd Bolzon, Director, bought 307,692 with an average share price of $13.00 per share and the total transaction amounting to $3,999,996.00.
  • On 2/18/2014 A/S Novo, Insider, bought 692,308 with an average share price of $13.00 per share and the total transaction amounting to $9,000,004.00.
  • On 12/17/2014 A/S Novo, Major Shareholder, bought 500,000 with an average share price of $17.00 per share and the total transaction amounting to $8,500,000.00.
  • On 2/26/2015 Neil Bodick, Insider, sold 4,000 with an average share price of $22.44 per share and the total transaction amounting to $89,760.00.
  • On 3/4/2015 Neil Bodick, Insider, sold 4,000 with an average share price of $23.45 per share and the total transaction amounting to $93,800.00.
  • On 3/10/2015 Neil Bodick, Insider, sold 4,000 with an average share price of $24.26 per share and the total transaction amounting to $97,040.00.

    • Analyst Ratings For Flexion Therapeutics Inc. (NASDAQ:FLXN)
    These are 7 Buy Ratings, 1 Strong Buy RatingThe current consensus rating for Flexion Therapeutics Inc. (NASDAQ:FLXN) is Buy (Score: 3.13) with a consensus target price of $31.38 , a potential (68.97% upside)

    Analyst Ratings History For Flexion Therapeutics Inc. (NASDAQ:FLXN)

    • On 3/30/2015 MLV & Co. Initiated Coverage of rating Buy with a price target of $38.00
    • On 9/2/2015 Northland Securities Reiterated Rating Buy with a price target of $40.00
    • On 5/27/2016 Needham & Company LLC Reiterated Rating Buy with a price target of $28.00 to $34.00
    • On 7/1/2016 Janney Montgomery Scott Reiterated Rating Buy with a price target of $30.00
    • On 6/30/2016 Wells Fargo & Co. Reiterated Rating Buy
    • On 6/30/2016 Royal Bank Of Canada Reiterated Rating Buy
    • On 9/6/2016 Lake Street Capital Reiterated Rating Buy with a price target of $38.00

    About Flexion Therapeutics Inc. (NASDAQ:FLXN)
    Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company’s other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.

    Recent Trading Activity for Flexion Therapeutics Inc. (NASDAQ:FLXN)
    Shares of Flexion Therapeutics Inc. closed the previous trading session at 18.57 0.00 0.00% with 621,857 shares trading hands.